NCT05972928CompletedPhase 2/3
Effect of Sitagliptin on Polycystic Ovarian Syndrome Patients
Effect of Sitagliptin on Clinical, Metabolic and Hormonal Parameters in Polycystic Ovarian Syndrome Patients
Source: ClinicalTrials.gov · Last updated 1 Sept 2026
Brief summary (registry, in English)
The Study aims to determine the proposed positive influence of Sitagliptin in manipulating hormonal , metabolic and inflammatory parameters in the treatment of Polycystic ovary syndrome and subsequent infertility
- Status (registry)
- Completed
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 25 Jul 2023
- Start date
- 7 Aug 2024
- Primary completion date
- 30 Apr 2025
- Lead sponsor
- Beni-Suef University
- NCT number
- NCT05972928
What you commit to
- Study type: Interventional · Phase 2/3
- Participants enrolled: 80
- From 7 Aug 2024 to the primary completion date, 30 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Diabetic on Metformin or any another antidiabetic drugs affecting insulin resistance
- documented use of oral hormonal contraceptives and hormone-releasing implants in the past 6 months prior to study entry 7.Lipid lowering Consumption
Other illness
- Brittle control of a thyroid disorder
- chronic kidney disease
Other
- congenital adrenal hyperplasia
- liver dysfunction
Who the study is looking for
- polycystic ovary syndrome usually diagnosed based on the Rotterdam criteria if 2 of 3 criteria are present:
- oligo- and/or anovulation
- hyperandrogenism (HA) (clinical and/or biochemical)
- polycystic ovary morphology (PCOM) on ultrasonography (either 12 or more follicles measuring 2-9 mm in diameter and/or an increased ovarian volume \>10 cm3).
Age in the registry: 20 years to 40 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beni-Suef University Hospital Coordinator of this site? Confirm its status | Banī Suwayf | Egypt | Unknown status |
Related publications
- The role of sitagliptin in modifying metabolic, hormonal and clinical parameters in polycystic ovarian syndrome patients: a randomized controlled trial.Front Pharmacol · 2026 · PMID 42871447
This page is information, not medical advice. Discuss any trial with your doctor.